Spinal Cord Injury (SCI), as a devastating and life-altering neurological disorder, is one of
the most serious health issues. Currently, the management of acute SCI includes pharmacotherapy and
surgical decompression. Both the approaches have been observed to have adverse physiological effects
on SCI patients. Therefore, novel therapeutic targets for the management of SCI are urgently required
for developing cell-based therapies. Multipotent stem cells, as a novel strategy for the treatment of
tissue injury, may provide an effective therapeutic option against many neurological disorders. Mesenchymal
stem cells (MSCs) or multipotent stromal cells can typically self-renew and generate various
cell types. These cells are often isolated from bone marrow (BM-MSCs), adipose tissues (AD-MSCs),
umbilical cord blood (UCB-MSCs), and placenta (PMSCs). MSCs have remarkable potential for the
development of regenerative therapies in animal models and humans with SCI. Herein, we summarize
the therapeutic potential of human MSCs in the treatment of SCI.
Keywords: Spinal cord injury, cell-based therapies, stem cells, mesenchymal stem cells, devastating disease, somatic stem cells.
Rights & PermissionsPrintExport